7 Analysts Have This To Say About Intellia Therapeutics
Portfolio Pulse from Benzinga Insights
Intellia Therapeutics (NASDAQ:NTLA) has received mixed analyst ratings over the past three months, with a decrease in the average 12-month price target from $62.17 to $53.43. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Intellia is a gene editing company focused on Crispr/Cas9-based therapeutics, facing challenges with a -48.82% revenue growth decline and a high net margin of -2112.62%.
October 25, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics has received mixed analyst ratings, with a decrease in the average 12-month price target from $62.17 to $53.43. The company faces a -48.82% decline in revenue growth, but maintains a strong net margin of -2112.62%.
The decrease in the average price target and the mixed analyst ratings suggest a negative short-term outlook for Intellia Therapeutics. The significant decline in revenue growth further supports a bearish sentiment, despite the strong net margin.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100